Engflag

Dolopar TAB

Quick links to important sections

Dolopar TAB

Dolopar TAB_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolopar TAB

What is Dolopar TAB?

Dolopar TAB is a pharmaceutical formulation primarily used for its analgesic and antipyretic properties. It is designed to help manage pain and reduce elevated body temperature.

Composition and Class

The medication belongs to a class of drugs known as analgesics (pain relievers) and antipyretics (fever reducers). The active ingredient in Dolopar TAB works by inhibiting the synthesis of specific chemical messengers in the central nervous system that are responsible for signaling pain and regulating body temperature.

Primary Uses

Dolopar TAB is commonly utilized to address various types of mild to moderate discomfort and febrile conditions. Its primary functions include:

  • Pain Management: It is used to provide relief from headaches, muscle aches, toothaches, and backaches.
  • Fever Reduction: It helps in lowering high body temperature associated with common colds, flu, or other infections.

Mechanism of Action

The therapeutic effect is achieved by elevating the overall pain threshold of the body and acting on the heat-regulating center in the brain. By affecting these biological pathways, the medication helps the body return to a more comfortable state during illness or physical strain.

What side effects are possible with Dolopar TAB?

Possible Side Effects and Safety Information

Official regulatory documentation classifies the potential side effects of this medicine based on the frequency and the System-Organ Class affected. Adverse reactions are primarily grouped by the component responsible for the effect.

Effects associated with the Caffeine component often relate to the central nervous and psychiatric systems, with a frequency classified as Not Known (derived from post-marketing data). These include nervousness, dizziness, insomnia, anxiety, restlessness, irritability, and palpitations.

Effects associated with the Paracetamol component include serious, albeit Very Rare, systemic reactions. These classified risks encompass severe blood disorders (such as thrombocytopaenia), immune system disorders (including anaphylaxis and angioedema), and hepatobiliary disorders (hepatic dysfunction).

Serious adverse reactions documented in official labeling include the potential for severe skin reactions (such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Acute Generalised Exanthematous Pustulosis) and the risk of severe liver damage or failure, primarily linked to excessive exposure or overdose.

Safety considerations for specific populations and exposure patterns are defined in regulatory documents. Caution is advised in patients with existing hepatic or renal impairment. The product is generally not recommended for use during pregnancy due to the caffeine component and is contraindicated for children under 12 years of age. Furthermore, regulatory warnings caution against the concurrent use of any other product containing paracetamol due to the increased risk of liver toxicity, and advise limiting excessive total daily caffeine intake from all sources.

Overdose and Emergency Response

Overdose involving this combination medicine is primarily characterized by the severe toxicological potential of the Paracetamol component. Early clinical manifestations documented in regulatory sources include anorexia, nausea, vomiting, and abdominal pain. The Caffeine component contributes acute symptoms of CNS overstimulation, such as tremor, agitation, and cardiac effects like tachycardia or palpitations.

The most serious, life-threatening outcome officially documented is dose-dependent acute hepatic necrosis, which can progress to liver failure, metabolic acidosis, and coma. Due to this risk, the government regulatory mandate is absolute: Seek immediate medical attention and contact emergency services immediately following any suspected overdose, even if the individual appears to be asymptomatic. Urgent hospital assessment is required to manage the potential for severe, delayed toxicity.

The official regulatory documents confirm that a specific antidote, N-acetylcysteine (NAC), is available and must be administered to mitigate the effects of Paracetamol. Management involves supportive treatment and mandatory clinical observation with laboratory monitoring, including liver function tests (LFTs) and Prothrombin Time (PT/INR). An increased risk of severe hepatic injury is explicitly noted for patients with underlying chronic alcoholism, malnutrition, or pre-existing liver disease, which requires special consideration during assessment.

Therapeutic Uses of Dolopar TAB

What Dolopar TAB Treats: Main Uses and Benefits

The primary role of Dolopar TAB is used to provide symptomatic relief. This combination is applied across domains where additional symptomatic support is needed and is relevant in contexts marked by increased discomfort. This information aligns with the therapeutic indications for this combination.

The medicine is commonly used to help with episodic or fluctuating pain patterns, including discomfort from tension headaches, minor dental work, musculoskeletal aches, and primary dysmenorrhea (menstrual cramps). It is also relevant for easing elevated body temperature (fever) associated with conditions where symptoms may intensify temporarily.

“This medication is applied in scenarios where additional management of discomfort is required, provides support that helps ease the overall symptom load during symptomatic periods.”

This supportive relief is relevant for managing symptoms that interfere with daily comfort.

Quick Fact: Relief for Pain and Fever This combination is primarily used across conditions characterized by acute or disruptive episodes and is relevant for easing symptom clusters that may become intense or disruptive, such as the simultaneous presence of fever and generalized body aches.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dolopar TAB? (Official Regulatory Information)

The population eligibility for using this fixed-dose combination (Paracetamol and Caffeine) is defined by official regulatory criteria, specifically listing groups for whom use is contraindicated or restricted.

Contraindicated Populations (Must Not Use)

The medicine is strictly contraindicated for patients with a known hypersensitivity or allergy to Paracetamol, Caffeine, or any excipients in the tablet formulation. It must also not be used by individuals with severe hepatocellular insufficiency or by those concurrently taking any other product containing Paracetamol.

Age and Physiological Restrictions

Population Group Eligibility Status
Pediatric Use Not recommended for children under the minimum age specified by the label (e.g., typically under 12 years).
Pregnancy Not recommended due to the caffeine component.
Lactation Not recommended, as both components are excreted in breast milk.

Conditional Use (Caution Advised)

Official labeling advises caution for patients with pre-existing conditions, including renal impairment, moderate hepatic impairment (liver disease), chronic alcohol use, anxiety disorders, or arrhythmia. Use is established for adults and the elderly who do not fall into any restricted categories.

What should I know about interactions with other medicines?

The official interaction profile for Dolopar TAB, a combination of Paracetamol and Caffeine, is structured around specific risks and requirements documented in regulatory labels. A primary mandatory restriction prohibits the co-administration of any other Paracetamol-containing product due to the severe risk of exceeding the safe cumulative dose, which may result in liver damage.

Interactions affecting drug exposure include those that alter metabolism. Substances documented as hepatic enzyme inducers, such as Phenytoin, Rifampicin, or chronic use of Alcohol, increase the formation of the toxic Paracetamol metabolite via the cytochrome P450 pathway, thereby heightening the risk of hepatotoxicity. This risk is officially noted to be increased in patients with pre-existing hepatic impairment or chronic alcoholism. Probenecid is documented to reduce Paracetamol clearance by inhibiting its conjugation, resulting in increased plasma exposure.

Interactions affecting absorption require timing adjustments. Cholestyramine significantly reduces Paracetamol absorption and necessitates a mandatory separation rule: it must not be given within one hour of this medicine. Conversely, medicines like Metoclopramide or Domperidone may accelerate the rate of Paracetamol absorption.

Pharmacodynamic interactions include the potential for Warfarin and other Coumarins to have an enhanced anticoagulant effect with prolonged, high-dose Paracetamol use. The Caffeine component requires limiting intake of dietary caffeine (e.g., coffee, tea) to avoid documented stimulant adverse effects.

Mechanism of Action

How Dolopar TAB Works — Mechanism of Action

Central Suppression of Prostaglandin Synthesis

This mechanism relies on the paracetamol component primarily acting within the Central Nervous System (CNS) to reduce the production of key signaling molecules mathbfPGE2. This action modulates the body's thermostatic set-point in the hypothalamus and dampens overactive pain signals traveling through the spinal cord, leading to the physiological consequences of decreased body temperature set-point and dampened ascending pain signals.

Adenosine Receptor Antagonism and Mechanistic Adjuvancy

The caffeine component acts as a non-selective antagonist (blocker) of adenosine receptors (mathbfA1 and mathbfA2A) in the brain and periphery. This mechanism mediates central nervous system stimulation and induces cerebral vasoconstriction (narrowing of blood vessels in the brain). This mechanism, which includes its role as an adjuvant, modifies the effect profile by influencing both vascular tone and the magnitude of central pain pathway modulation.

Integrated Modulation via Mechanistic Synergy

The combination produces a mechanistic synergy by engaging both the central prostaglandin pathway and the adenosinergic system. This leads to integrated modulation across these distinct biological pathways, influencing the overall dampening of pain signal transmission.

Dosage and Administration Information

How to Use Dolopar TAB

The usage of the Paracetamol and Caffeine combination tablet is structured around standardized, label-based administration principles. The approved route of administration is oral, and the tablet is directed to be swallowed whole with water, independent of meals. The regimen follows a precise, time-interval-based schedule.

For adults and adolescents aged 16 years and over, the standard single dose is two tablets. This dose may be repeated, provided that a minimum interval of four hours has elapsed since the previous intake. The framework imposes a strict maximum limit of eight tablets (corresponding to 4000 mg Paracetamol and 520 mg Caffeine) over any 24-hour period, a critical procedural rule.

Administration is generally defined as short-term use, and the medicine should be used at the lowest necessary dose for the shortest duration. A core procedural constraint is the absolute requirement not to use this product concurrently with any other medications that contain Paracetamol. This constraint is in place to ensure compliance with established daily intake limits.

Specific dosing principles apply to younger populations: use is generally not recommended for children under 12 years. For adolescents aged 12 to 15 years, a distinct, lower single dose of one tablet is established, and the maximum intake for this age group is restricted to four tablets in 24 hours.

Recent Clinical Evidence

Evidence for use in Acute Mild to Moderate Pain

Research has primarily focused on the combination of Paracetamol and Caffeine in contexts relevant in trials assessing short-term or episodic pain patterns. Studies were conducted as rigorous, single-dose Randomized Controlled Trials (RCTs) involving adults with conditions such as tension-type headaches and post-operative dental pain. Research highlights patterns where the combination was associated with an increased proportion of participants achieving defined endpoints for acute pain relief compared to Paracetamol alone. However, follow-up durations were limited to the immediate hours following administration, meaning the findings primarily contextualize short-term changes.

Evidence for Symptomatic Relief of Fever

The combination’s role in easing fever is primarily supported by the Paracetamol component. Research relies on the Paracetamol component's pharmacological classification, which has been studied in contexts related to antipyresis. While studies monitored temperature reduction in general adult populations, limited information is available from specific research designed to examine if the addition of Caffeine alters the fever-reducing effect over Paracetamol alone.

Long-Term Studies and Durability of Effect

The majority of high-quality research has been applied in studies examining short-term symptom patterns only. Consequently, long-term effects are not fully established. Follow-up durations were limited, meaning the evidence base does not extensively monitor how effects might be sustained over weeks or months of repeated use.

Evidence in Specific Patient Populations

The primary body of evidence, including most RCTs and meta-analyses, reflects studies where the results apply mainly to general adult populations experiencing acute pain. Data for certain groups remain insufficient. For instance, limited information is available for older adults (ge 65 years). The findings describe group patterns, not personal outcomes, and the applicability of the results to these specific individuals is not established.

Overview of Evidence Gaps and Research Uncertainties

Researchers note that evidence gaps persist in several key areas. The most significant gap is the heavy focus on single-dose administration, which limits information for long-term outcomes. Furthermore, comparative evidence is lacking for certain head-to-head trials against other common non-opioid pain relievers.

Key Studies & References VI.2 Elements for a Public Summary (Regulatory Risk Management Plan for Paracetamol/Caffeine)

Frequently Asked Questions (FAQ)

Common questions about Dolopar TAB (FAQ)

Q: What are the proper storage conditions for this drug?

According to the official drug labeling, Dolopar TAB must be stored under specific conditions to ensure its quality. This usually involves storing the product at a certain temperature and protecting it from excessive moisture or light. Improper storage conditions could potentially affect the quality and effectiveness of the medication.

Q: Will this drug affect my ability to drive or operate machinery?

Official regulatory documents include warnings regarding the potential effects of this drug. The official labeling specifies whether potential side effects, such as drowsiness or dizziness, may affect the ability to perform tasks that require mental alertness, such as driving or operating heavy machinery.

Q: Is this drug safe for children under 12 years old?

The official product information specifies the age groups for which the safety and effectiveness of Dolopar TAB have been established. If the drug's label does not include directions for children under 12, or specifically contraindicates its use in that age group, it is generally not recommended for use in this population.

Q: Is it safe to use this drug for a long period of time?

Regulatory documents contain detailed warnings and precautions related to drug use, including information on potential risks associated with long-term therapy. For some medications, the official labeling may specify a maximum duration of use or require specific patient monitoring for certain risks that can occur when the drug is taken over an extended period.

How should Dolopar TAB be stored and disposed of?

How to Store and Dispose of Dolopar TAB?

This medicine must be stored strictly according to the conditions documented in regulatory labeling to maintain stability and effectiveness.

Storage and Disposal Requirement Official Regulatory Instruction
Temperature Condition Store below 25 C or 30 C (check specific product label), and away from excess heat.
Environmental Protection Keep in the original container, sealed, and protected from light and moisture.
Child Safety Rule Must be kept out of the sight and reach of children and pets.
Disposal Instructions Unused or expired product should be discarded through an official drug take-back program or by mixing with an undesirable substance in a sealed bag for household trash. Do not flush down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dolopar TAB found in:

A-Z Index: